{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"description":"The maximum grade for each type of AE will be recorded for each patient, and frequency tables will be reviewed to determine patterns. Additionally, the relationship of the AE(s) to the study treatment will be taken into consideration.","groups":[{"description":"Patients receive ixazomib citrate PO on days 1, 8, and 15 and ibrutinib PO daily on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.\\>\n\n\\> Ibrutinib: Given PO\\>\n\n\\> Ixazomib Citrate: Given PO\\>\n\n\\> Laboratory Biomarker Analysis: Correlative studies\\>\n\n\\> Pharmacodynamic Study: Correlative studies\\>\n\n\\> Pharmacokinetic Study: Correlative studies","id":"OG000","title":"Treatment (Ixazomib Citrate, Ibrutinib)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Number of Patients Experiencing Grade 3+ Adverse Effects (AE) Graded According to Common Terminology Criteria for Adverse Events (CTCAE) Version (v.) 4.0","type":"SECONDARY","unitOfMeasure":"Participants"}